Company news

Neuroone Medical Technologies Corporation (NASDAQ:NMTC) news

Every Neuroone Medical Technologies Corporation press release and news update in one place — announcements, filings coverage, and company updates for investors.

Neuroone Medical Technologies Corporation (NASDAQ:NMTC) news

Press releases & updates

NeuroOne(R) to Report Third Quarter Fiscal Year 2026 Financial Results on Thursday, August 13, 2026, at 8:30 a.m. Eastern Time

NeuroOne Releases CNS Drug Delivery White Paper Ahead of Planned Fiscal Year-End Availability of the StereoCED(TM) Platform

NeuroOne(R) Highlights Potential Paradigm Shift for Patients Treated With the OneRF(R) Brain Ablation System Based on Reports by Physicians

NeuroOne(R) Expands Drug Delivery Program Through Collaboration on Pediatric Brain Cancer Clinical Trial

NeuroOne(R) Added to Russell Microcap(R) Index

NeuroOne(R) Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NeuroOne(R) Announces Preliminary Inclusion in Russell Microcap(R) Index

NeuroOne Medical Technologies : Amendment to Quarterly Report (Form 10-Q/A)

NeuroOne(R) to Present at the Planet MicroCap Las Vegas 2026 Conference Wednesday, June 17, 2026 at 12:00 p.m. Pacific Time

NeuroOne(R) to Present at the 2026 American Society for Stereotactic and Functional Neurosurgery Biennial Meeting on May 31, 2026

NeuroOne(R) Medical Technologies Announces Restatement of Financial Results for Quarter Ending March 31, 2026

NeuroOne Reports Fiscal Q2 2026 Financial Results and Provides Corporate Business Update

NeuroOne(R) Regains Compliance With Nasdaq Listing Requirement

NeuroOne(R) Announces Chief Financial Officer Succession Plan

NeuroOne(R) to Report Second Quarter Fiscal Year 2026 Financial Results on Tuesday, May 12 at 8:30 a.m. Eastern Time

NeuroOne(R) Medical Technologies Announces Reverse Stock Split to Regain Nasdaq Compliance

NeuroOne(R) Medical Technologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NeuroOne(R) Successfully Completes Limited Market Release of OneRF(R) Trigeminal Nerve Ablation System

NeuroOne(R) Announces Publication of Clinical Experience With Its OneRF(R) sEEG-Guided Radiofrequency Ablation Technology

NeuroOne(R) to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference March 17, 2026 at 1:20 p.m. Eastern Time

NeuroOne(R) Issues Shareholder Letter and Provides Corporate Update

NeuroOne(R) Appoints David Wambeke as Chief Business Officer; Concurrently Completes Insider Purchase of 1 Million Shares

NeuroOne(R) to Host Virtual Investor Webinar on Thursday, March 12, 2026 at 11:30 a.m. Eastern Time

NeuroOne Reports Fiscal Q1 2026 Financial Results; Expects Product Revenue of At Least $10.5 Million in Fiscal Year 2026

NeuroOne(R) to Report First Quarter Fiscal Year 2026 Financial Results on Tuesday, February 17 at 8:30 a.m. Eastern Time

NeuroOne(R) Appoints Jason Mills to the Board of Directors

NeuroOne Reports Strong Fourth Quarter Fiscal 2025 Financial Results With Product Revenue Growth of 907% to $2.7 Million and 55.8% Gross ...

NeuroOne(R) to Report Fourth Quarter and Fiscal Year 2025 Financial Results on Wednesday, December 17th at 8:30 a.m. Eastern Time

NeuroOne(R) Announces Initial Successful Cases Completed With OneRF(R) Trigeminal Nerve Ablation System at the University Hospitals in Cl...

NeuroOne(R) Announces Upcoming Industry Conference Participation

NeuroOne(R) Receives 180-Day Extension From Nasdaq to Regain Minimum Bid Price Compliance

NeuroOne Promotes Emily Johns to Chief Administrative Officer

NeuroOne(R) Bolsters Patent Portfolio With Recent Decisions From Both the U.S. Patent & Trademark Office and European Patent Office

NeuroOne Announces Preliminary Unaudited Product Revenue Growth of 163% to Record $9.1 Million, Invitation to Join Virtual Investor Webin...

NeuroOne(R) Announces Virtual Investor Webinar on October 7, 2025 at 8:30 a.m. EST

NeuroOne® to Participate in Sidoti Small-Cap Conference on September 17th and 18th, 2025

NeuroOne Receives FDA 510(k) Clearance for OneRF Trigeminal Nerve Ablation System to Treat Facial Pain

NeuroOne® Receives FDA 510(k) Clearance for OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain

NeuroOne® Reports Third Quarter Fiscal Year 2025 Financial Results; Revenue Increases 105% YoY and Gross Margin Expands to 53.9%

NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results on Thursday, August 14 at 8:30 a.m. Eastern Time - Update

NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results on Thursday, August 14 at 8:30 a.m. Eastern Time

NeuroOne® Receives Notice of Allowance for Key Patent from U.S. Patent & Trademark Office

NeuroOne® Patient Surpasses One Year Milestone of Seizure Freedom Following Treatment with OneRF® Ablation System

NeuroOne Strengthens Leadership Team with Appointment of Emily Johns as General Counsel and Corporate Secretary

NeuroOne to Attend MedInvest’s MedTech, AI & Digital Health Conference on June 3-4, 2025

NeuroOne® Reports Second Quarter Fiscal Year 2025 Financial Results; Gross Margin Improves Significantly YoY to 55.6%

NeuroOne Appoints Renowned Neurosurgeon Dr. Parag Patil as Chief Medical Advisor

NeuroOne Medical Announces Participation in The D. Boral Capital Inaugural Global Conference

NeuroOne® to Report Second Quarter Fiscal Year 2025 Financial Results on Tuesday, May 13 at 8:30 a.m. Eastern Time

NeuroOne® Completes FDA Submission for the OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain